CINP Schizophrenia Guidelines – References

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

 

Agid, O., Kapur, S., Arenovich, T., Zipursky, R.B., 2003. Delayed-onset hypothesis of antipsychotic action – A hypothesis tested and rejected. Arch.Gen.Psychiatry 60, 1228-1235.

Akerele, E., Levin, F.R., 2007. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am.J.Addict. 16, 260-268.

Akhondzadeh, S., Tabatbaee, M., Amini, H., Ahmadi Abhari, S.A., Abbasi, S.H., Behnam, B., 2007. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr.Res. 90, 179-185.

Alexander, J., Tharyan, P., Adams, C., John, T., Mol, C., Philip, J., 2004. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting – Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. British Journal of Psychiatry 185, 63-69.

Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C., Infante, M.C., Weiden, P.J., 1999. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am.J.Psychiatry 156, 1686-1696.

Amato, L., Minozzi, S., Pani, P.P., Davoli, M., 2007. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev, CD006306.

Andreasen, N., Carpenter, W., Kane, J., Lasser, R., Marder, S., Weinberger, D., 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am.J.Psychiatry 62, 441-449.

Arango, C., Robles, O., Parellada, M., Fraguas, D., Ruiz-Sancho, A., Medina, O., Zabala, A., Bombin, I., Moreno, D., 2009. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. European child & adolescent psychiatry 18, 418-428.

Ascher-Svanum, H., Nyhuis, A.W., Faries, D.E., Kinon, B.J., Baker, R.W., Shekhar, A., 2007. Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia. Schizophr.Bull.

Azima, H., Arthurs, D., Silver, A., 1962. The effects of chlordiazepoxide (librium) in anxiety states. A multi-blind study. Can Psychiatr Assoc J 7, 44-50.

Barbui, C., Saraceno, B., Liberati, A., Garattini, S., 1996. Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. Eur.Psychiatry 11, 306-311.

Barbui, C., Signoretti, A., Mule, S., Boso, M., Cipriani, A., 2009. Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment? Schizophrenia Bulletin 35, 458-468.

Basan, A., Leucht, S., 2004. Valproate for schizophrenia. Cochrane.Database.Syst.Rev., CD004028.

Battaglia, J., Moss, S., Rush, J., Kang, J., Mendoza, R., Leedom, L., Dubin, W., McGlynn, C., Goodman, L., 1997. Haloperidol, Lorazepam, or both for psychotic agitation: a multicenter, prospective, double blind, emergency department study. AMERICAN JOURNAL OF EMERGENCY MEDICINE 15, 335-340.

Bhidayasiri, R., Fahn, S., Weiner, W.J., Gronseth, G.S., Sullivan, K.L., Zesiewicz, T.A., American Academy of, N., 2013. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 81, 463-469.

Biederman, J., Lerner, Y., Belmaker, R.H., 1979. Combination of lithium carbonate and haloperidol in schizo-affective patients. Archives of General Psychiatry 36, 327-333.

Bollini, P., 1994. Antipsychotic drugs: is more worse? A meta analysis of the published randomized controlled trials. Psychol.Med. 24, 307-316.

Boter, H., Peuskens, J., Libiger, J., Fleischhacker, W.W., Davidson, M., Galderisi, S., Kahn, R.S., group, E.s., 2009. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 115, 97-103.

Buchanan, R.W., Conley, R.R., Dickinson, D., Ball, M.P., Feldman, S., Gold, J.M., McMahon, R.P., 2008. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165, 82-89.

Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P.R., Keller, W., 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr.Bull. 36, 71-93.

Caemmerer, J., Correll, C.U., Maayan, L., 2012. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 140, 159-168.

Caligiuri, M.R., Jeste, D.V., Lacro, J.P., 2000. Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs & aging 17, 363-384.

Carpenter, W.T., Hanlon, T.E., Heinrichs, D.W., Summerfelt, A.T., Kirkpatrick, B., Levine, J., Buchanan, R.W., 1990. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am.J.Psychiatry 147, 1138-1163.

Casey, D.E., Carson, W.H., Saha, A., Liebeskind, A., Ali, M.W., Jody, D., Ingenitoon, G.G., group, A.s., 2003. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 166, 391-399.

Casey, D.E., Daniel, D.G., Tamminga, C., Kane, J.M., Tran-Johnson, T., Wozniak, P., bi-Saab, W., Baker, J., Redden, L., Greco, N., Saltarelli, M., 2009. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 34, 1330-1338.

Chang, Y.C., Lane, H.Y., Yang, K.H., Huang, C.L., 2006. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 26, 554-559.

Cheine, M., Ahonen, J., Wahlbeck, K., 2003. Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review). The Cochrane Library.

Chen, E.Y.H., Hui, C.L.M., Lam, M., Law, C.W., Chiu, C.P.Y., Chung, D.W.S., Tso, S., Pang, E.P.F., Chan, K.T., Wong, Y.C., Mo, F., Chan, K.P.M., Yao, T.J., Hung, S.F., Honer, W.G., 2010. A double-blind randomized placebo-controlled study of relapse prevention in remitted first-episode psychosis patients following one year of maintenance therapy. BMJ 341, c4024.

Cheung, H.K., 1981. Schizophrenics fully remitted on neuroleptics for 3-5 years – to stop or continue drugs? British Journal of Psychiatry 138, 490-494.

Chouinard, G., Jones, B.D., 1980. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137, 16-21.

Chua, W.L., Santiago, A.D., Kulkarni, J., Mortimer, A., 2005. Estrogen for schizophrenia. Cochrane Database of Systematic Reviews.

Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., Purgato, M., Spineli, L.M., Goodwin, G.M., Geddes, J.R., 2011. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378, 1306-1315.

Citrome, L., 2007a. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin.Psychiatry 68, 1876-1885.

Citrome, L., 2007b. The psychopharmacology of violence with emphasis on schizophrenia, part 1: acute treatment. J Clin Psychiatry 68, 163-164.

Citrome, L., 2007c. The psychopharmacology of violence with emphasis on schizophrenia, part 2: long-term treatment. J Clin Psychiatry 68, 331-332.

Citrome, L., 2007d. The psychopharmacology of violence with emphasis on schizophrenia, part 2: long-term treatment. J Clin Psychiatry 68, 331-332.

Citrome, L., Casey, D.E., Daniel, D.G., Wozniak, P., Kochan, L.D., Tracy, K.A., 2004. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr Serv 55, 290-294.

Citrome, L., Shope, C.B., Nolan, K.A., Czobor, P., Volavka, J., 2007. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol 22, 356-362.

Correll, C., Agarwal, V., Kane, J., 2011. Gradual and Overlapping Antipsychotic Switch Strategies Are Associated with Less All-Cause Discontinuation in

Schizophrenia: Results from a Meta-analysis of Different Switch Strategies, ACNP 2011.

Correll, C.U., 2010. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. European psychiatry : the journal of the Association of European Psychiatrists 25 Suppl 2, S12-21.

Correll, C.U., Malhotra, A.K., Kaushik, S., McMeniman, M., Kane, J.M., 2003. Early prediction of antipsychotic response in schizophrenia. Am.J.Psychiatry 160, 2063-2065.

Correll, C.U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J.M., Malhotra, A.K., 2009a. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302, 1765-1773.

Correll, C.U., Penzner, J.B., Parikh, U.H., Mughal, T., Javed, T., Carbon, M., Malhotra, A.K., 2006. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child and adolescent psychiatric clinics of North America 15, 177-206.

Correll, C.U., Rummel-Kluge, C., Corves, C., Kane, J.M., Leucht, S., 2009b. Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr.Bull. 35, 443-457.

Correll, C.U., Schenk, E.M., 2008. Tardive dyskinesia and new antipsychotics. Curr.Opin.Psychiatry 21, 151-156.

Crocq, M.A., Naber, D., Lader, M.H., Thibaut, F., Drici, M., Everitt, B., Hall, G.C., Le Jeunne, C., Mittoux, A., Peuskens, J., Priori, S., Sturkenboom, M., Thomas, S.H., Tanghoj, P., Toumi, M., Mann, R., Moore, N.D., 2010. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20, 829-838.

Crossley, N.A., Constante, M., McGuire, P., Power, P., 2010. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196, 434-439.

Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W.W., Keefe, R.S., Boter, H., Keet, I.P., Prelipceanu, D., Rybakowski, J.K., Libiger, J., Hummer, M., Dollfus, S., Lopez-Ibor, J.J., Hranov, L.G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rossler, A., Kahn, R.S., 2009. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166, 675-682.

Davis, J.M., Chen, N., Glick, I.D., 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch.Gen.Psychiatry 60, 553-564.

Davis, J.M., Mentalon, L., Watanabe, M.D., 1994. Depot antipsychotic drugs. Place in therapy. Drugs 47, 741-773.

De Hert, M., Cohen, D., Bobes, J., Cetkovich-Bakmas, M., Leucht, S., Ndetei, D.M., Newcomer, J.W., Uwakwe, R., Asai, I., Moller, H.J., Gautam, S., Detraux, J., Correll, C.U., 2011a. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World psychiatry : official journal of the World Psychiatric Association 10, 138-151.

de Hert, M., Correll, C.U., Bobes, J., Cetkovich-Bakmas, M., Cohen, D., Asai, I., Detraux, J., Gautam, S., Moller, H.J., Ndetei, D.M., Newcomer, J.W., Uwakwe, R., Leucht, S., 2011b. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World psychiatry : official journal of the World Psychiatric Association 10, 52-77.

De Hert, M., Dobbelaere, M., Sheridan, E.M., Cohen, D., Correll, C.U., 2011c. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European psychiatry : the journal of the Association of European Psychiatrists 26, 144-158.

de Lucena, D., Fernandes, B.S., Berk, M., Dodd, S., Medeiros, D.W., Pedrini, M., Kunz, M., Gomes, F.A., Giglio, L.F., Lobato, M.I., Belmonte-de-Abreu, P.S., Gama, C.S., 2009. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 70, 1416-1423.

Dixon, L.B., Dickerson, F., Bellack, A.S., Bennett, M., Dickinson, D., Goldberg, R.W., Lehman, A., Tenhula, W.N., Calmes, C., Pasillas, R.M., Peer, J., Kreyenbuhl, J., Schizophrenia Patient Outcomes Research, T., 2010. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 36, 48-70.

Dold, M., Fugger, G., Aigner, M., Lanzenberger, R., Kasper, S., 2015. Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 166, 187-193.

Dold, M., Li, C., Tardy, M., Khorsand, V., Gillies, D., Leucht, S., 2012. Benzodiazepines for schizophrenia, Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

Ehrenreich, H., Hinze-Selch, D., Stawicki, S., Aust, C., Knolle-Veentjer, S., Wilms, S., Heinz, G., Erdag, S., Jahn, H., Degner, D., Ritzen, M., Mohr, A., Wagner, M., Schneider, U., Bohn, M., Huber, M., Czernik, A., Pollmacher, T., Maier, W., Siren, A.L., Klosterkotter, J., Falkai, P., Ruther, E., Aldenhoff, J.B., Krampe, H., 2007. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Molecular Psychiatry 12, 206-220.

Elias, A., Kumar, A., 2007. Testosterone for schizophrenia. Cochrane Database Syst Rev, CD006197.

Emsley, R., Fleischhacker, W.W., 2013. Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified? Schizophr Res 150, 427-433.

Emsley, R.A., Group, R.W., 1999. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr.Bull. 25, 721-729.

Essock, S.M., Covell, N.H., Davis, S.M., Stroup, T.S., Rosenheck, R.A., Lieberman, J.A., 2006. Effectiveness of switching antipsychotic medications. Am J Psychiatry 163, 2090-2095.

Essock, S.M., Schooler, N.R., Stroup, T.S., McEvoy, J.P., Rojas, I., Jackson, C., Covell, N.H., Schizophrenia Trials, N., 2011. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168, 702-708.

Faulkner, G., Cohn, T., Remington, G., 2007. Interventions to reduce weight gain in schizophrenia, Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd.

Fleischhacker, W.W., Heikkinen, M.E., Olie, J.P., Landsberg, W., Dewaele, P., McQuade, R.D., Loze, J.Y., Hennicken, D., Kerselaers, W., 2010. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 13, 1115-1125.

Fleischhacker, W.W., Uchida, H., 2014. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 17, 1083-1093.

Fraguas, D., Correll, C.U., Merchan-Naranjo, J., Rapado-Castro, M., Parellada, M., Moreno, C., Arango, C., 2011. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 21, 621-645.

Gaebel, W., Riesbeck, M., Wolwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., Lemke, M., Heuser, I., Maier, W., Huff, W., Schmitt, A., Sauer, H., Riedel, M., Klingberg, S., Kopcke, W., Ohmann, C., Moller, H.J., German Study Group on First-Episode, S., 2011. Relapse prevention in first-episode schizophrenia–maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 72, 205-218.

Gallego, J.A., Nielsen, J., De Hert, M., Kane, J.M., Correll, C.U., 2012. Safety and tolerability of antipsychotic polypharmacy. Expert opinion on drug safety 11, 527-542.

Gallego, J.A., Robinson, D.G., Sevy, S.M., Napolitano, B., McCormack, J., Lesser, M.L., Kane, J.M., 2011. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry 72, 1691-1696.

Gardner, D.M., Murphy, A.L., O’Donnell, H., Centorrino, F., Baldessarini, R.J., 2010. International consensus study of antipsychotic dosing. Am J Psychiatry 167, 686-693.

Geddes, J., Freemantle, N., Harrison, P., Bebbington, P., 2000. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321, 1371-1376.

Goodwin, G., Fleischhacker, W., Arango, C., Baumann, P., Davidson, M., de, H.M., Falkai, P., Kapur, S., Leucht, S., Licht, R., Naber, D., O’Keane, V., Papakostas, G., Vieta, E., Zohar, J., 2009. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur.Neuropsychopharmacol. 19, 520-532.

Gundlach, R., Engelhardt, D.M., Hankoff, L., Paley, H., Rudorfer, L., Bird, E., 1966. A double-blind outpatient study of diazepam (Valium) and placebo. Psychopharmacologia 9, 81-92.

Haddad, P.M., Wieck, A., 2004. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64, 2291-2314.

Hamann, J., Cohen, R., Leucht, S., Busch, R., Kissling, W., 2007. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry 68, 992-997.

Hamann, J., Leucht, S., Kissling, W., 2003. Shared decision making in psychiatry. Acta Psychiatrica Scandinavica 107, 403-409.

Hatta, K., Otachi, T., Sudo, Y., Hayakawa, T., Ashizawa, Y., Takebayashi, H., Hayashi, N., Hamakawa, H., Ito, S., Nakase, R., Usui, C., Nakamura, H., Hirata, T., Sawa, Y., Group, J.S., 2011. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophr Res 128, 127-135.

Hatta, K., Otachi, T., Sudo, Y., Kuga, H., Takebayashi, H., Hayashi, H., Ishii, R., Kasuya, M., Hayakawa, T., Morikawa, F., Hata, K., Nakamura, M., Usui, C., Nakamura, H., Hirata, T., Sawa, Y., group, J.s., 2012. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. Psychiatry Res 198, 194-201.

Hausmann, A., Fleischhacker, W.W., 2002. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand 106, 83-96.

Hedges, D., Jeppson, K., Whitehead, P., 2003. Antipsychotic medication and seizures: a review. Drugs of today (Barcelona, Spain : 1998) 39, 551-557.

Herz, M.I., Glazer, W.M., Mostert, M.A., Sheard, M.A., Szymanski, H.V., Hafez, H., Mirza, M., Vana, J., 1991. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch.Gen.Psychiatry 48, 333-339.

Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Grunder, G., Haen, E., Havemann-Reinecke, U., Jaquenoud Sirot, E., Kirchherr, H., Laux, G., Lutz, U.C., Messer, T., Muller, M.J., Pfuhlmann, B., Rambeck, B., Riederer, P., Schoppek, B., Stingl, J., Uhr, M., Ulrich, S., Waschgler, R., Zernig, G., 2011. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44, 195-235.

Honer, W.G., MacEwan, G.W., Gendron, A., Stip, E., Labelle, A., Williams, R., Eriksson, H., Group, S.S., 2012. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry 73, 13-20.

Huf, G., Coutinho, E.S., Adams, C.E., 2007. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ 335, 869.

Huf, G., Coutinho, E.S.F., Adams, C.E., Borges, R.V.S., Ferreira, M.A.V., Silva, F.J.F., Pereira, A.J.C.R., Abreu, A.M., Lugao, S.M., Santos, M.P.C.P., Gewandsznajder, M., Mercadante, V.R.P., Lange, W., Dias, C.L., Brasil, M.A., Huf, G., Coutinho, E.S.F., Adams, C.E., Fagundes, H.M., Lopez, J.R.R.A., Lima, M., Campos, M.B., Rozenfeld, S., Braz, R.M., Struchiner, C.J., Camacho, L.B., Mari, J.D., 2003. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BRITISH MEDICAL JOURNAL 327, 708-711.

Jager, M., Schmauss, M., Laux, G., Pfeiffer, H., Naber, D., Schmidt, L.G., Gaebel, W., Klosterkotter, J., Heuser, I., Maier, W., Lemke, M.R., Degner, D., Buchkremer, G., Gastpar, M., Moller, H.J., Riedel, M., 2009. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. Eur.Psychiatry 24, 501-506.

Jolley, A.G., Hirsch, S.R., 1990. Trial brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. B.M.J. 301, 837-842.

Joy, C.B., Mumby-Croft, R., Joy, L.A., 2006. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews.

Kahn,

Kane, J.M., Detke, H.C., Naber, D., Sethuraman, G., Lin, D.Y., Bergstrom, R.F., McDonnell, D., 2010. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 167, 181-189.

Kane, J.M., Honigfeld, G., Singer, J., Meltzer, H., group, a.t.C.C.s., 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.

Kane, J.M., Marder, S.R., Schooler, N.R., Wirshing, W.C., Umbricht, D., Baker, R.W., Wirshing, D.A., Safferman, A., Ganguli, R., McMeniman, M., Borenstein, M., 2001. Clozapine and haloperidol in moderately refractory schizophrenia – A 6-month randomized and double-blind comparison. Arch.Gen.Psychiatry 58, 965-972.

Keefe, R.S.E., Bilder, R.M., Davis, S.M., Harvey, P.D., Palmer, B.W., Gold, J.M., Meltzer, H.Y., Green, M.F., Capuano, G., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Roscnheck, R.A., Perkins, D.O., Davis, C.E., Hsiao, J.K., Lieberman, J.A., 2007. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch.Gen.Psychiatry 64, 633-647.

Kim, J.H., Ryu, S., Nam, H.J., Lim, M., Baek, J.H., Joo, Y.H., Kwon, J.S., Ha, T.H., Hong, K.S., 2012. Symptom structure of antipsychotic-induced obsessive compulsive symptoms in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 39, 75-79.

Kinon, B.J., Basson, B.R., Gilmore, J.A., Malcolm, S., Stauffer, V.L., 2000. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 61, 833-840.

Kinon, B.J., Chen, L., scher-Svanum, H., Stauffer, V.L., Kollack-Walker, S., Zhou, W., Kapur, S., Kane, J.M., 2010. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35, 581-590.

Kinon, B.J., Kane, J.M., Johns, C., Perovich, R., Ismi, M., Koreen, A., Weiden, P., 1993. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol.Bull. 29, 309-314.

Kinon, B.J., scher-Svanum, H., Adams, D.H., Chen, L., 2008a. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials. J.Clin.Psychopharmacol. 28, 544-549.

Kinon, B.J., Volavka, J., Stauffer, V., Edwards, S.E., Liu-Seifert, H., Chen, L., Adams, D.H., Lindenmayer, J.P., McEvoy, J.P., Buckley, P.F., Lieberman, J.A., Meltzer, H.Y., Wilson, D.R., Citrome, L., 2008b. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin.Psychopharmacol. 28, 392-400.

Kishi, T., Matsuda, Y., Iwata, N., Correll, C.U., 2013. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 74, e1169-1180.

Kishimoto, T., 2012. New results alter balance of evidence of meta-analysis on long-acting injectable vs. oral antipsychotics in schizophrenia Schizophr.Res. 136, S58.

Kishimoto, T., Agarwal, V., Kishi, T., Leucht, S., Kane, J.M., Correll, C.U., 2013a. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 18, 53-66.

Kishimoto, T., De Hert, M., Carlson, H.E., Manu, P., Correll, C.U., 2012. Osteoporosis and fracture risk in people with schizophrenia. Current opinion in psychiatry 25, 415-429.

Kishimoto, T., Nitta, M., Borenstein, M., Kane, J.M., Correll, C.U., 2013b. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 74, 957-965.

Kissling, W., Kane, J.M., Barnes, T.R., Dencker, K., Fleischhacker, W.W., Goldstein, J.M., Johnson, D.A.W., Marder, S.R., Müller-Spahn, F., Tegeler, J., Wistedt, B., Woggon, B., 1991. Guidelines for neuroleptic relapse prevention in schizophrenia: Towards consensus view, in: Kissling, W. (Ed.), Guidelines for neuroleptic relapse prevention in schizophrenia. Springer, Heidelberg, Berlin, pp. 155-163.

Klein, E., Bental, E., Lerer, B., Belmaker, R.H., 1984. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Archives of General Psychiatry 41, 165-170.

Komossa, K., Depping, A.M., Gaudchau, A., Kissling, W., Leucht, S., 2010. Second-generation antipsychotics for major depressive disorder and dysthymia. The Cochrane database of systematic reviews, CD008121.

Krakowski, M.I., Czobor, P., Citrome, L., Bark, N., Cooper, T.B., 2006. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch.Gen.Psychiatry 63, 622-629.

Kumra, S., Frazier, J.A., Jacobsen, L.K., McKenna, K., Gordon, C.T., Lenane, M.C., Hamburger, S.D., Smith, A.K., Albus, K.E., AlaghbandRad, J., Rapoport, J.L., 1996. Childhood-onset schizophrenia – A double-blind clozapine-haloperidol comparison. Archives of General Psychiatry 53, 1090-1097.

Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H.M., De Thomas, C., Kafantaris, V., Correll, C.U., Kane, J.M., 2008. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 63, 524-529.

Lambert, M., Schimmelmann, B.G., Naber, D., Eich, F.X., Schulz, H., Huber, C.G., Karow, A., 2009. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry 42, 277-283.

Lavin, M.R., Rifkin, A., 1991a. Prophylactic Antiparkinson Drug-Use. 1. Initial Prophylaxis and Prevention of Extrapyramidal Side-Effects. J.Clin.Pharmacol. 31, 763-768.

Lavin, M.R., Rifkin, A., 1991b. Prophylactic Antiparkinson Drug-Use. 2. Withdrawal After Long-Term Maintenance Therapy. J.Clin.Pharmacol. 31, 769-777.

Lee, J.G., Lee, S.W., Lee, B.J., Park, S.W., Kim, G.M., Kim, Y.H., 2012. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry investigation 9, 166-173.

Leucht, S., Arbter, D., Engel, R.R., Kissling, W., Davis, J.M., 2009a. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol.Psychiatry 14, 429-447.

Leucht, S., Busch, R., Hamann, J., Kissling, W., Kane, J.M., 2005. Early onset of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol.Psychiatry 57, 1543-1549.

Leucht, S., Busch, R., Kissling, W., Kane, J.M., 2007a. Early prediction of antipsychotic non-response. J.Clin.Psychiatry 68, 352-360.

Leucht, S., Cipriani, A., Spineli, L.M., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R.R., Geddes, J.R., Kissling, W., Stapf, M.P., Lässig, B., Salanti, G., Davis, J.M., 2013a. Multiple treatments meta-analysis on the efficacy and tolerability of 15 antipsychotic drugs in schizophrenia. Lancet Accepted for publication.

Leucht, S., Cipriani, A., Spineli, L.M., Öerey, D., Richter, F., Samara, M., Barbui, C., Engel, R., Geddes, J., Kissling, W., Stapf, M.P., Lässig, B., Salanti, G., Davis, J.M., 2013b. Multiple treatments meta-analysis on the efficacy and tolerability of 15 antipsychotic drugs in schizophrenia. Lancet.

Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C., Davis, J.M., 2009b. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41.

Leucht, S., Heres, S., Kissling, W., Davis, J.M., 2011. Evidence-based pharmacotherapy of schizophrenia. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 14, 269-284.

Leucht, S., Kissling, W., Engel, R.R., Davis, J.M., 2009c. Are new drugs for schizophrenia better than old ones? Reply. Lancet 373, 1249-1250.

Leucht, S., Kissling, W., McGrath, J., 2007b. Lithium for schizophrenia, Cochrane Database Syst.Rev. Wiley & Sons, p. CD003834.

Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., Davis, J.M., 2009d. A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166, 152-163.

Leucht, S., McGrath, J., White, P., Kissling, W., 2007c. Carbamazapine for schizophrenia and schizoaffective psychoses. The Cochrane Library.

Leucht, S., Pitschel-Walz, G., Engel, R., Kissling, W., 2002. Amisulpride – an unusual atypical antipsychotic. A meta-analysis of randomized controlled trials. Am.J.Psychiatry 159, 180-190.

Leucht, S., Samara, M., Heres, S., Patel, M.X., Furukawa, T., Cipriani, A., Geddes, J., Davis, J.M., 2015a. Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. Schizophr Bull.

Leucht, S., Samara, M., Heres, S., Patel, M.X., Woods, S.W., Davis, J.M., 2014. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40, 314-326.

Leucht, S., Shamsi, A.S., Busch, R., Kissling, W., Kane, J.M., 2008. Early prediction of antipsychotic response. Replication and six weeks extension. Schizophr.Res., epub ahead of print.

Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., Davis, J.M., 2012. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379, 2063-2071.

Leucht, S., Winter-van Rossum, I., Heres, S., Arango, C., Fleischhacker, W.W., Glenthoj, B., Leboyer, M., Leweke, F.M., Lewis, S., McGuire, P., Meyer-Lindenberg, A., Rujescu, D., Kapur, S., Kahn, R.S., Sommer, I.E., 2015b. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull 41, 549-558.

Levine, S.Z., Rabinowitz, J., Ascher-Svanum, H., Faries, D.E., Lawson, A.H., 2011. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res 133, 42-46.

Lieberman, J.A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X.D., Gage, A., Group, M.-M.-S., 2009. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34, 1322-1329.

Lieberman, J.A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z.K.G., Hamer, R.M., 2003. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28, 995-1003.

Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K., 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N.Engl.J.Med. 353, 1209-1223.

Lima, A.R., Bacalcthuk, J., Barnes, T.R., Soares-Weiser, K., 2004a. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev, CD001946.

Lima, A.R., Soares-Weiser, K., Bacaltchuk, J., Barnes, T.R., 2002. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev, CD001950.

Lima, A.R., Weiser, K.V., Bacaltchuk, J., Barnes, T.R., 2004b. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev, CD003727.

Lin, C.H., Chou, L.S., Lin, C.H., Hsu, C.Y., Chen, Y.S., Lane, H.Y., 2007. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J.Clin.Psychiatry 68, 1522-1527.

Lindenmayer, J.P., Citrome, L., Khan, A., Kaushik, S., Kaushik, S., 2011. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 31, 160-168.

Lindenmayer, J.P., Khan, A., Iskander, A., Abad, M.T., Parker, B., 2007. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin.Psychiatry 68, 368-379.

McClellan, J., Sikich, L., Findling, R.L., Frazier, J.A., Vitiello, B., Hlastala, S.A., Williams, E., Ambler, D., Hunt-Harrison, T., Maloney, A.E., Ritz, L., Anderson, R., Hamer, R.M., Lieberman, J.A., 2007. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. Journal of the American Academy of Child and Adolescent Psychiatry 46, 969-978.

McEvoy, J.P., Byerly, M., Hamer, R.M., Dominik, R., Swartz, M.S., Rosenheck, R.A., Ray, N., Lamberti, J.S., Buckley, P.F., Wilkins, T.M., Stroup, T.S., 2014. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311, 1978-1987.

McEvoy, J.P., Hogarty, G.E., Steingard, S., 1991. Optimal dose of neuroleptic in acute schizophrenia. Arch.Gen.Psychiatry 48, 740-745.

Meltzer, H.Y., Alphs, L., Green, A.I., Altamura, A.C., Anand, R., Bertoldi, A., Bourgeois, M., Chouinard, G., Islam, M.Z., Kane, J., Krishnan, R., Lindenmayer, J.P., Potkin, S., 2003. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen.Psychiatry 60, 82-91.

Meltzer, H.Y., Bastani, B., Kwon, K.Y., Ramirez, L.F., Burnett, S., Sharpe, J., 1989. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 99 Suppl, S68-S72.

Miller, C.H., Fleischhacker, W.W., 2000. Managing antipsychotic-induced acute and chronic akathisia. Drug safety : an international journal of medical toxicology and drug experience 22, 73-81.

Minervini, M.G., Priore, P., Farolfi, A., Cesana, B., Morselli, P.L., 1990. Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients. Pharmacopsychiatry 23, 102-106.

Mishara, A.L., Goldberg, T.E., 2004. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55, 1013-1022.

Mizuno, Y., Suzuki, T., Nakagawa, A., Yoshida, K., Mimura, M., Fleischhacker, W.W., Uchida, H., 2014. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40, 1385-1403.

Moncrieff, J., 2006. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114, 3-13.

Morphy, M.A., 1986. A double-blind comparison of alprazolam and placebo in the treatment of anxious schizophrenic outpatients. Current therapeutic research 40, 551-560.

Muller, D.J., Kekin, I., Kao, A.C., Brandl, E.J., 2013. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. International review of psychiatry 25, 554-571.

Nolte, S., Wong, D., Latchford, G., 2004. Amphetamines for schizophrenia. Cochrane Database of Systematic Reviews.

Organisation, W.H., 2010. mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings: Mental Health Gap Action Programme (mhGAP). World Health Organisation, Switzerland.

Petrakis, I.L., Nich, C., Ralevski, E., 2006. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 32, 644-654.

Petrides, G., Malur, C., Braga, R.J., Bailine, S.H., Schooler, N.R., Malhotra, A.K., Kane, J.M., Sanghani, S., Goldberg, T.E., John, M., Mendelowitz, A., 2015. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry 172, 52-58.

Peuskens, J., Group., R.S., 1995. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br.J.Psychiatry 166, 712-726.

Pietzcker, A., Gaebel, W., Koepcke, W., Linden, M., Mueller, P., Mueller-Spahn, F., Tegeler, J., 1993. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia – 2-year results of a German multicenter study. Journal of Psychiatric Research 27, 321-339.

Poyurovsky, M., 2010. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry 196, 89-91.

Premkumar, T.S., Pick, J., 2006. Lamotrigine for schizophrenia. Cochrane Database Syst Rev, CD005962.

Rappard, F., Müller, N., 2004. Celecoxib Add-on Therapy Does Not Have Beneficial Antipsychotic Effects Over Risperidone Alone in Schizophrenia. Neuropsychopharmacology 29(Suppl 1), S222.

Rauch, A.S., Fleischhacker, W.W., 2013. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. Cns Drugs 27, 637-652.

Raveendran, N.S., Tharyan, P., Alexander, J., Adams, C.E., 2007. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ 335, 865.

Remington, G., Chue, P., Stip, E., Kopala, L., Girard, T., Christensen, B., 2005. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 76, 267-272.

Robinson, D., Woerner, M.G., Alvir, J.M., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Lieberman, J.A., 1999a. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56, 241-247.

Robinson, D.G., Woerner, M.G., Alvir, J.M.J., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Bilder, R., Goldman, R., Lieberman, J.A., 1999b. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am.J.Psychiatry 156, 544-549.

Rosenheck, R., Cramer, J., Xu, W.C., Thomas, J., Henderson, W., Frisman, L., Fye, C., Charney, D., 1997. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N.Engl.J.Med. 337, 809-815.

Rubio, G., Martinez, I., Ponce, G., Jimenez-Arriero, M.A., Lopez-Munoz, F., Alamo, C., 2006. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian journal of psychiatry. Revue canadienne de psychiatrie 51, 531-539.

Rummel, C., Kissling, W., Leucht, S., 2006. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews.

Rybakowski, J.K., Vansteelandt, K., Remlinger-Molenda, A., Fleischhacker, W.W., Kahn, R.S., Peuskens, J., Group, E.S., 2014. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 24, 1500-1505.

Saha, S., Chant, D., McGrath, J., 2007. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64, 1123-1131.

Samaha, A.N., Seeman, P., Stewart, J., Rajabi, H., Kapur, S., 2007. Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. The Journal of neuroscience : the official journal of the Society for Neuroscience 27, 2979-2986.

Samara, M.T., Leucht, C., Leeflang, M.M., Anghelescu, I.G., Chung, Y.C., Crespo-Facorro, B., Elkis, H., Hatta, K., Giegling, I., Kane, J.M., Kayo, M., Lambert, M., Lin, C.H., Moller, H.J., Pelayo-Teran, J.M., Riedel, M., Rujescu, D., Schimmelmann, B.G., Serretti, A., Correll, C.U., Leucht, S., 2015. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. Am J Psychiatry 172, 617-629.

Sampath, G., Shah, A., Krska, J., Soni, S.D., 1992. Neuroleptic discontinuation in the very stable schizophrenic patient – relapse rates and serum neuroleptic levels. Human Psychopharmacology 7, 255-264.

Sayers, S.L., Campbell, E.C., Kondrich, J., Mann, S.C., Cornish, J., O’Brien, C., Caroff, S.N., 2005. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J.Nerv.Ment.Dis. 193, 379-386.

Scheltema Beduin, A.A., Swets, M., Machielsen, M., Korver, N., Genetic, R., Outcome of Psychosis, I., 2012. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. J Clin Psychiatry 73, 1395-1402.

Schennach-Wolff, R., Seemuller, F.H., Mayr, A., Maier, W., Klingberg, S., Heuser, I., Klosterkotter, J., Gastpar, M., Hafner, H., Sauer, H., Schneider, F., Gaebel, W., Jager, M., Moller, H.J., Riedel, M., 2010. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry 196, 460-466.

Schimmelmann, B.G., Schmidt, S.J., Carbon, M., Correll, C.U., 2013. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Current opinion in psychiatry 26, 219-230.

Schirmbeck, F., Zink, M., 2012. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Current neuropharmacology 10, 88-95.

Schooler, N.R., Keith, S.J., Severe, J.B., Matthews, S.M., Bellack, A.S., Glick, I.D., Hargreaves, W.A., Kane, J.M., Ninan, P.T., Frances, A., Jacobs, M., Lieberman, J.A., Mance, R., Simpson, G.M., Woerner, M.G., 1997. Relapse and rehospitalization during maintenance treatment of schizophrenia. Arch.Gen.Psychiatry 54, 453-463.

Sepehry, A.A., Potvin, S., Elie, R., Stip, E., 2007. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J.Clin.Psychiatry 68, 604-610.

Shalev, A., Hermesh, H., Rothberg, J., Munitz, H., 1993. Poor Neuroleptic Response in Acutely Exacerbated Schizophrenic-Patients. Acta Psychiatrica Scandinavica 87, 86-91.

Shepherd, M., Watt, D., Falloon, I., Smeeton, N., 1989. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol.Med.Suppl. 15, 1-46.

Sherwood, M., Thornton, A.E., Honer, W.G., 2012. A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine. J Psychopharmacol 26, 1175-1184.

Sikich, L., 2008. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 69 Suppl 4, 21-25.

Sikich, L., Frazier, J.A., McClellan, J., Findling, R.L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A.E., Michael, E., De Jong, S., Slifka, K., Noyes, N., Hlastala, S., Pierson, L., McNamara, N.K., Delporto-Bedoya, D., Anderson, R., Hamer, R.M., Lieberman, J.A., 2008. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165, 1420-1431.

Silvestri, S., Seeman, M.V., Negrete, J.C., Houle, S., Shammi, C.M., Remington, G.J., Kapur, S., Zipursky, R.B., Wilson, A.A., Christensen, B.K., Seeman, P., 2000. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 152, 174-180.

Singh, S.P., Singh, V., Kar, N., Chan, K., 2010. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 197, 174-179.

Siris, S.G., 1993. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. British Journal of Psychiatry 163, 22-78.

Smith, R.C., Infante, M., Singh, A., Khandat, A., 2001. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int.J.Neuropsychopharmacol. 4, 239-250.

Soares, K.V., McGrath, J.J., 1999. The treatment of tardive dyskinesia–a systematic review and meta-analysis. Schizophr Res 39, 1-16; discussion 17-18.

Sommer, I.E., Begemann, M.J., Temmerman, A., Leucht, S., 2011. Pharmacological Augmentation Strategies for Schizophrenia Patients With Insufficient Response to Clozapine: A Quantitative Literature Review. Schizophr Bull.

Sommer, I.E., de Witte, L., Begemann, M., Kahn, R.S., 2012. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 73, 414-419.

Stip, E., Sepehry, A.A., Chouinard, S., 2007. Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. Clin.Neuropharmacol. 30, 218-229.

Strawn, J.R., Keck, P.E., Jr., Caroff, S.N., 2007. Neuroleptic malignant syndrome. Am J Psychiatry 164, 870-876.

Stroup, T.S., Lieberman, J.A., McEvoy, J.P., Swartz, M.S., Davis, S.M., Capuano, G.A., Rosenheck, R.A., Keefe, R.S.E., Miller, A.L., Belz, I., Hsiao, J.K., 2007. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. Am.J.Psychiatry 164, 415-427.

Stroup, T.S., McEvoy, J.P., Ring, K.D., Hamer, R.H., LaVange, L.M., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Nussbaum, A.M., Lieberman, J.A., Schizophrenia Trials, N., 2011. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168, 947-956.

Suzuki, T., Uchida, H., Watanabe, K., Nomura, K., Takeuchi, H., Tomita, M., Tsunoda, K., Nio, S., Den, R., Manki, H., Tanabe, A., Yagi, G., Kashima, H., 2007. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?–A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berl) 195, 285-295.

Taylor, D.M., Smith, L., Gee, S.H., Nielsen, J., 2012. Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125, 15-24.

Tharyan, P., Adams, C.E., 2005. Electroconvulsive therapy for schizophrenia (Cochrane Review). The Cochrane Library.

Tiihonen, J., Haukka, J., Taylor, M., Haddad, P.M., Patel, M.X., Korhonen, P., 2011. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168, 603-609.

Tiihonen, J., Wahlbeck, K., Kiviniemi, V., 2009. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophr.Res. 109, 10-14.

Tiihonen, J., Wahlbeck, K., Lonnqvist, J., Klaukka, T., Ioannidis, J.P.A., Volavka, J., Haukka, J., 2006. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333, 224-227.

Trikalinos, T.A., Churchill, R., Ferri, M., Leucht, S., Tuunainen, A., Wahlbeck, K., Ioannidis, J.P.A., 2004. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J.Clin.Epidemiol. 57, 1124-1130.

Tuominen, H.J., Tiihonen, J., Wahlbeck, K., 2006. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews.

Uchida, H., Suzuki, T., Takeuchi, H., Arenovich, T., Mamo, D.C., 2009. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr.Bull. epub ahead of print.

Van Putten, T., 1978. Akinetic depression in schizophrenia. Arch.Gen.Psychiatry 35, 1101-1107.

Volavka, J., Czobor, P., Derks, E.M., Bitter, I., Libiger, J., Kahn, R.S., Fleischhacker, W.W., Group, E.S., 2011. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry 72, 955-961.

Wahlbeck, K., Cheine, M., Essali, M.A., Rezk, E., 1999. Clozapine vs typical neuroleptic medication for schizophrenia. Cochrane Database Syst.Rev. 2, CD000059.

Wang, C.Y., Xiang, Y.T., Cai, Z.J., Weng, Y.Z., Bo, Q.J., Zhao, J.P., Liu, T.Q., Wang, G.H., Weng, S.M., Zhang, H.Y., Chen, D.F., Tang, W.K., Ungvari, G.S., Risperidone Maintenance Treatment in Schizophrenia, i., 2010. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry 167, 676-685.

Waraich, P., Adams, C., Hammill, K., Marti, J., Roque, M., 2002. Haloperidol dose for the acutely ill phase of schizophrenia. Cochrane Database Syst.Rev. 2, CD001951.

Whitehead, C., Moss, S., Cardno, A., Lewis, G., 2003. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol.Med. 33, 589-599.

Woodward, N.D., Purdon, S.E., Meltzer, H.Y., Zald, D.H., 2005. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine and risperidone in schizophrenia. Int.J.Neuropsychopharmacol. 8, 1-16.

Wunderink, L., Nieboer, R.M., Wiersma, D., Sytema, S., Nienhuis, F.J., 2013. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA psychiatry 70, 913-920.

Wunderink, L., Nienhuis, F.J., Sytema, S., Slooff, C.J., Knegtering, R., Wiersma, D., 2007. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin.Psychiatry 68, 654-661.

Zhang, J.P., Gallego, J.A., Robinson, D.G., Malhotra, A.K., Kane, J.M., Correll, C.U., 2012. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum, 1-14.

Zhang, J.P., Lencz, T., Malhotra, A.K., 2010. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 167, 763-772.

Zimbroff, D.L., Kane, J.M., Tamminga, C.A., Daniel, D.G., Mack, R.J., Wozniak, P.J., Sebree, T.B., Wallin, B.A., Kashkin, K.B., Adan, F., Ainslie, G., Allan, E., Atri, P., Baker, R., Beitman, B., Brown, G., Canive, J., Carman, J., Dott, S., Edwards, J., Fenton, W., Freidli, J., Funderburg, L., Ereshefsky, L., Gladson, M., Hamilton, J., Haque, S., Hartford, J., Horne, R., Houck, C., Jampala, C., Labelle, A., Larson, G., Liesem, M., Liskow, B., Makela, E., Moore, N., Morphy, M., Posever, T., Risch, S., Rotrosen, J., Sheehan, D., Silverstone, P., Swann, A., Tapp, A., Thomas, M., Volavka, J., Vora, S., 1997. Controlled, dose response study of sertindole and haloperidol in the treatment of schizophrenia. Am.J.Psychiatry 154, 782-791.

Zipursky, R.B., Menezes, N.M., Streiner, D.L., 2014. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 152, 408-414.

back-arrow

Get the CINP app:
Android

itunes